Acute Kidney Injury (AKI) Phase I

Published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.

Next up:

Non-Alcoholic Fatty Liver (NAFL)

Completed human clinical trial to study the effects of Basis on liver fat accumulation in healthy adults with fatty liver; results will be announced in 2022 and published by 2023.

Acute Kidney Injury (AKI) Phase II

Initiated at Mayo Clinic, the human clinical trial will evaluate the efficacy of Basis for the prevention of AKI in patients that have undergone a cardiac surgery; primary study completion date October 2023.

Repeat Dose Basis

Elysium’s first human clinical trial showed that a daily dose of Basis is a safe and effective way to sustainably increase NAD+ levels by an average of 40% from baseline.